A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502681-24-00

Acronym

64407564MMY1005

Enrollment

Registered

2024-04-26

Start date

2022-06-22

Completion date

Unknown

Last updated

2025-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026